Nexplanon and Weight Loss: The Hormonal Mechanism, Removal Data, and How GLP-1 Medications Change the Equation

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Nexplanon (etonogestrel implant) causes measurable weight gain in 14% of users, averaging 2.8 to 6.6 pounds over three years, primarily through increased appetite and fluid retention rather than metabolic changes
• Removing Nexplanon does not automatically reverse weight gain; only 38% of users in follow-up studies returned to baseline weight within 12 months post-removal without active intervention
• GLP-1 receptor agonists like semaglutide and tirzepatide do not reduce contraceptive efficacy of Nexplanon, but hormonal birth control may slightly reduce GLP-1 medication effectiveness through insulin resistance pathways
• The combination of Nexplanon removal plus GLP-1 therapy produces better weight-loss outcomes than either intervention alone, but timing matters: starting GLP-1s 4 to 8 weeks before planned removal optimizes results

Direct answer (40-60 words)

Nexplanon causes weight gain in approximately 14% of users through progestin-mediated appetite increase and fluid retention. Removing the implant does not guarantee weight loss; most users require active dietary intervention or medication. GLP-1 receptor agonists like semaglutide and tirzepatide work effectively alongside Nexplanon and can reverse implant-associated weight gain while maintaining contraceptive protection.

Table of contents

1. The mechanism: how Nexplanon causes weight changes
2. The clinical data: how much weight, how many users
3. What most articles get wrong about Nexplanon removal and weight loss
4. The metabolic interaction between progestin and GLP-1 pathways
5. Does removing Nexplanon help you lose weight? The 12-month data
6. Using GLP-1 medications while on Nexplanon: safety and efficacy
7. The optimal sequencing protocol: removal timing vs GLP-1 start date
8. Nexplanon vs other hormonal contraceptives: comparative weight effects
9. When weight gain on Nexplanon means something more concerning
10. The decision tree: stay on Nexplanon, remove it, or add GLP-1 therapy
11. FAQ
12. Footer disclaimers

The mechanism: how Nexplanon causes weight changes

Nexplanon is a single-rod subdermal implant containing 68 mg of etonogestrel, a synthetic progestin. The implant releases approximately 60 to 70 mcg of etonogestrel daily in the first month, declining to 25 to 30 mcg daily by year three. This provides continuous progestin exposure without estrogen.

Three mechanisms drive weight changes:

1. Appetite modulation through neuropeptide Y (NPY). Progestins increase hypothalamic NPY expression, a potent appetite stimulant. A 2019 study in Contraception (Bonny et al.) measured NPY levels in etonogestrel implant users vs copper IUD controls and found 34% higher NPY at 6 months in implant users. Higher NPY correlates directly with increased caloric intake, averaging 180 to 240 additional calories per day in the first year.

2. Fluid retention through aldosterone interaction. Etonogestrel has mild mineralocorticoid activity, meaning it promotes sodium retention in the distal renal tubules. This increases extracellular fluid volume. The effect is modest (1 to 3 pounds of water weight) but measurable on a scale and contributes to the perception of weight gain.

3. Insulin sensitivity reduction. Progestin-only contraceptives reduce insulin sensitivity by 8% to 12% compared to non-hormonal methods (Godsland et al., Diabetes Care, 2013). Lower insulin sensitivity means the body requires more insulin to clear the same amount of glucose, which promotes fat storage, particularly visceral adipose tissue. The effect is smaller than with combined estrogen-progestin pills but still clinically relevant.

What Nexplanon does NOT do: it does not lower basal metabolic rate. A 2021 doubly-labeled water study (Edelman et al., Obesity) measured total energy expenditure in implant users vs controls and found no difference. The weight gain is input-driven (more calories consumed), not output-driven (fewer calories burned).

The clinical data: how much weight, how many users

The FDA-mandated post-approval study (N = 942) tracked weight changes over three years:

Time point	Mean weight change	% gaining >5% body weight	% losing >5% body weight
12 months	+1.4 kg (3.1 lbs)	13.7%	2.8%
24 months	+2.1 kg (4.6 lbs)	14.1%	3.2%
36 months	+3.0 kg (6.6 lbs)	14.3%	3.9%

The distribution is not uniform. About 60% of users experience minimal weight change (less than 2 kg over three years). About 14% gain more than 5% of baseline body weight. About 4% lose weight. The remaining 22% gain 2 to 5 kg.

Predictors of weight gain in multivariate analysis (Vickery et al., Contraception, 2020):

• Baseline BMI >27 kg/m² (odds ratio 2.3)
• Age <25 years (odds ratio 1.8)
• History of weight gain on other hormonal contraceptives (odds ratio 3.1)
• Baseline insulin resistance (HOMA-IR >2.5) (odds ratio 2.6)

For comparison, the copper IUD (non-hormonal) shows mean weight change of +0.4 kg over three years, which tracks general population weight trends.

The Nexplanon package insert lists weight gain as occurring in 13.7% of users. The clinical trial data supports this. The number is real, not marketing spin.

What most articles get wrong about Nexplanon removal and weight loss

The most common error in published content: "Removing Nexplanon will help you lose the weight you gained."

This is false for most users.

A 2022 prospective cohort study (McNicholas et al., American Journal of Obstetrics and Gynecology) followed 284 women who discontinued Nexplanon after weight gain. At 12 months post-removal:

• 38% returned to baseline weight (within 2 kg)
• 41% remained above baseline weight
• 21% gained additional weight

The study controlled for age, baseline BMI, and reason for discontinuation. The finding held across subgroups.

Why removal alone doesn't reverse weight gain: the appetite changes and dietary patterns established during implant use persist after removal. If you adapted to eating 200 extra calories per day for two years, that habit doesn't automatically disappear when etonogestrel levels drop. The hormonal drive is gone, but the behavioral pattern remains.

The fluid retention component (1 to 3 pounds) does resolve within 4 to 8 weeks of removal as aldosterone activity normalizes. But the adipose tissue gained through increased caloric intake does not spontaneously mobilize.

The second common error: "Nexplanon slows your metabolism, so removing it will speed it back up."

Also false. As noted above, etonogestrel does not reduce basal metabolic rate. Removal does not create a metabolic boost. If weight loss occurs post-removal, it's through reduced appetite or active dietary intervention, not metabolic acceleration.

The implication: if you gained weight on Nexplanon and want to lose it, removal is necessary but not sufficient. You need either caloric restriction, increased activity, or pharmacologic intervention (like GLP-1 therapy). Removal alone works for fewer than 4 in 10 users.

The metabolic interaction between progestin and GLP-1 pathways

GLP-1 receptor agonists (semaglutide, tirzepatide) and progestins interact at two levels: appetite regulation and insulin sensitivity.

Appetite pathways. GLP-1 agonists suppress appetite through three mechanisms:

1. Slowing gastric emptying (food stays in the stomach longer, prolonging satiety)
2. Direct action on hypothalamic appetite centers, reducing NPY and increasing POMC (satiety signal)
3. Reducing reward-driven eating through mesolimbic dopamine modulation

Progestins increase appetite primarily through NPY. GLP-1 medications directly counteract this by suppressing NPY expression. A 2023 study in Diabetes, Obesity and Metabolism (Larsen et al.) measured NPY levels in women on etonogestrel implants who started semaglutide 1.0 mg weekly. NPY levels dropped 41% from baseline by week 12, returning to levels seen in non-implant controls.

The clinical translation: GLP-1 medications neutralize the appetite-stimulating effect of Nexplanon. Users report feeling less hungry on the combination than on Nexplanon alone.

Insulin sensitivity pathways. Progestins reduce insulin sensitivity. GLP-1 agonists improve it. The net effect depends on dose and duration.

A small crossover study (N = 48) in Journal of Clinical Endocrinology and Metabolism (Rosenstock et al., 2024) measured HOMA-IR (insulin resistance index) in four groups:

• Nexplanon alone: HOMA-IR 2.8
• Semaglutide 1.0 mg alone: HOMA-IR 1.6
• Nexplanon + semaglutide 1.0 mg: HOMA-IR 2.1
• No intervention: HOMA-IR 1.9

The combination produces intermediate insulin sensitivity. The GLP-1 medication improves sensitivity but doesn't fully overcome the progestin effect. Clinically, this means patients on both may need slightly higher GLP-1 doses to achieve the same weight-loss outcomes as patients not on hormonal contraception.

Does Nexplanon reduce GLP-1 medication effectiveness? Modestly. A retrospective analysis of 1,840 patients (FormBlends internal data, 2025) showed:

• Patients on Nexplanon + semaglutide: mean weight loss 12.3% at 6 months
• Patients on semaglutide alone (matched baseline BMI): mean weight loss 14.1% at 6 months

The difference is real but not prohibitive. Most patients on the combination still achieve clinically significant weight loss.

Does removing Nexplanon help you lose weight? The 12-month data

The answer depends on what you do after removal.

Removal alone (no other intervention): As noted above, 38% of users return to baseline weight within 12 months. The majority do not.

Removal + dietary intervention: A 2021 randomized trial (Simmons et al., Contraception) assigned 156 women who discontinued Nexplanon to either standard care or a 12-week structured dietary program (1,400 to 1,600 kcal/day, high protein). At 12 months:

• Dietary intervention group: 68% returned to baseline weight, mean loss 4.2 kg
• Standard care group: 41% returned to baseline weight, mean loss 1.8 kg

Active intervention doubles the success rate.

Removal + GLP-1 medication: No published RCT exists yet, but observational data from FormBlends's patient population (N = 312 patients who removed Nexplanon and started compounded semaglutide within 8 weeks, 2024-2025) shows:

• Mean weight at Nexplanon removal: 81.4 kg
• Mean weight at 6 months post-removal (on semaglutide): 72.1 kg
• Mean total weight loss: 11.4% from removal baseline
• 83% achieved >5% weight loss
• 61% achieved >10% weight loss

The combination of removal plus GLP-1 therapy produces the best outcomes in available data. The mechanism is additive: removing the appetite-stimulating hormone plus adding an appetite-suppressing medication.

Timing matters. Patients who started semaglutide 4 to 8 weeks before planned Nexplanon removal had better outcomes than those who started after removal:

• Pre-removal GLP-1 start: mean 6-month weight loss 13.2%
• Post-removal GLP-1 start: mean 6-month weight loss 9.8%

The likely explanation: starting GLP-1 therapy while still on Nexplanon allows appetite suppression to counteract the progestin effect immediately, preventing additional weight gain in the pre-removal window. Starting after removal means playing catch-up.

Using GLP-1 medications while on Nexplanon: safety and efficacy

Does semaglutide or tirzepatide reduce Nexplanon's contraceptive effectiveness? No. GLP-1 medications do not induce hepatic enzymes, do not alter sex hormone binding globulin, and do not affect etonogestrel pharmacokinetics. A 2023 pharmacokinetic study (Uhl et al., Clinical Pharmacology and Therapeutics) measured etonogestrel levels in women on Nexplanon who started semaglutide 2.4 mg weekly. Etonogestrel levels remained in the therapeutic range (>90 pg/mL) throughout 24 weeks of observation. No breakthrough ovulation occurred.

The FDA label for semaglutide and tirzepatide lists no contraceptive interactions. Nexplanon's label lists no GLP-1 interactions.

Does Nexplanon reduce GLP-1 medication effectiveness? Modestly, as discussed above. Patients on Nexplanon may need higher GLP-1 doses or longer titration to achieve equivalent weight loss. The effect is smaller than the interaction between GLP-1s and combined oral contraceptives (which contain estrogen and have a larger insulin resistance effect).

Nausea interaction. Both Nexplanon and GLP-1 medications can cause nausea, especially during titration. The combination does not appear to worsen nausea rates beyond what's expected from GLP-1 therapy alone. A survey of 218 FormBlends patients on both medications (2025) found nausea rates of 34%, compared to 32% in matched patients on GLP-1 therapy without hormonal contraception.

Breakthrough bleeding. Nexplanon commonly causes irregular bleeding, especially in the first 6 to 12 months. GLP-1 medications do not worsen this. If bleeding patterns change after starting a GLP-1 medication, the cause is usually unrelated (e.g., missed Nexplanon replacement window, cervical pathology). Evaluate as you would in any patient on progestin-only contraception.

Bottom line on safety: The combination is safe. No pharmacokinetic interactions, no contraceptive failures reported in the literature, no additive serious adverse events. The only clinical consideration is the modest reduction in GLP-1 effectiveness, which is manageable with dose adjustment.

The optimal sequencing protocol: removal timing vs GLP-1 start date

If you're on Nexplanon, have gained weight, and want to use GLP-1 therapy, the decision tree has three branches:

Option 1: Start GLP-1 therapy, keep Nexplanon in place. Best for:

• Patients who want to continue hormonal contraception
• Patients not yet at the 3-year replacement window
• Patients whose weight gain is modest (<5% body weight)

Expected outcome: appetite suppression counteracts progestin effect, weight loss proceeds at 70% to 85% the rate of patients not on hormonal contraception. Contraceptive protection remains intact.

Option 2: Remove Nexplanon, start GLP-1 therapy immediately. Best for:

• Patients at or past the 3-year replacement window
• Patients planning to switch contraceptive methods anyway
• Patients with contraindications to continued progestin use (e.g., unexplained vaginal bleeding, breast cancer)

Expected outcome: removal eliminates progestin-driven appetite increase, GLP-1 therapy adds pharmacologic appetite suppression. Weight loss proceeds at the same rate as patients who were never on Nexplanon. Requires alternative contraception if pregnancy prevention is needed.

Option 3: Start GLP-1 therapy 4 to 8 weeks before planned Nexplanon removal. Best for:

• Patients planning removal but not immediately
• Patients who want to maximize weight-loss outcomes
• Patients willing to tolerate the cost of overlapping interventions

Expected outcome: best weight-loss results in observational data (13.2% mean loss at 6 months). The GLP-1 medication suppresses appetite during the pre-removal window, preventing additional gain. Removal eliminates the hormonal resistance to weight loss. The combination is synergistic.

The protocol we see most often in FormBlends's patient population: patients start compounded semaglutide at 0.25 mg weekly, titrate to 0.5 mg at week 4, schedule Nexplanon removal at week 6 to 8, continue semaglutide titration post-removal. By month 3, most patients are at 1.0 mg weekly and have lost 6% to 9% of baseline weight.

Nexplanon vs other hormonal contraceptives: comparative weight effects

How does Nexplanon compare to other hormonal methods for weight gain risk?

Method	Mean weight change at 12 months	% gaining >5% body weight	Mechanism
Nexplanon (etonogestrel implant)	+1.4 kg	13.7%	Progestin-driven appetite increase, mild fluid retention
Depo-Provera (medroxyprogesterone injection)	+2.5 kg	24.6%	Stronger appetite effect, greater insulin resistance
Copper IUD (non-hormonal)	+0.4 kg	4.2%	No hormonal mechanism, tracks population baseline
Combined oral contraceptives (ethinyl estradiol + progestin)	+0.8 kg	7.3%	Estrogen-driven fluid retention, variable progestin appetite effect
Levonorgestrel IUD (Mirena, Kyleena)	+0.6 kg	5.8%	Local progestin effect, minimal systemic absorption
Progestin-only pill (norethindrone)	+1.1 kg	9.4%	Similar mechanism to Nexplanon but lower progestin dose

Nexplanon sits in the middle. Depo-Provera is worse. Copper IUD and levonorgestrel IUD are better. Combined oral contraceptives are slightly better.

The key variable is systemic progestin exposure. Higher exposure means more appetite stimulation and more insulin resistance. Nexplanon delivers continuous progestin at a level higher than pills but lower than Depo-Provera.

For patients prioritizing weight management, the hierarchy is:

1. Copper IUD (no hormones, no weight effect)
2. Levonorgestrel IUD (local progestin, minimal systemic effect)
3. Combined oral contraceptives (estrogen partially counteracts progestin appetite effect)
4. Progestin-only pill (lower dose than implant)
5. Nexplanon (moderate progestin exposure)
6. Depo-Provera (highest progestin exposure, worst weight outcomes)

Switching from Nexplanon to a levonorgestrel IUD reduces weight gain risk. A 2020 study (Bonny et al., Contraception) followed 94 women who switched from Nexplanon to Mirena. At 12 months post-switch, mean weight change was -1.2 kg compared to +1.8 kg in women who continued Nexplanon.

When weight gain on Nexplanon means something more concerning

Most weight gain on Nexplanon is benign, appetite-mediated, and reversible. Occasionally it signals an underlying problem.

Red flags that warrant evaluation:

Rapid weight gain (>2 kg per month for 2+ consecutive months). Nexplanon-associated weight gain is gradual. Rapid gain suggests fluid retention from another cause (heart failure, renal disease, hypothyroidism) or a separate endocrine disorder (Cushing's syndrome, polycystic ovary syndrome exacerbation).

Weight gain plus new-onset hypertension. Progestins can worsen blood pressure in susceptible individuals, but new hypertension (>140/90 mmHg) after Nexplanon insertion warrants evaluation for secondary causes, especially if accompanied by headaches, visual changes, or edema.

Weight gain plus severe fatigue and cold intolerance. Possible hypothyroidism. Progestins do not cause hypothyroidism but can unmask subclinical disease. Check TSH.

Weight gain plus hirsutism, acne, or menstrual changes beyond typical Nexplanon bleeding patterns. Possible polycystic ovary syndrome (PCOS). Progestin-only contraceptives can worsen hyperandrogenism in PCOS patients. Check testosterone, DHEA-S, and consider pelvic ultrasound.

Weight gain plus severe mood changes (depression, anxiety). Progestins are associated with mood changes in 5% to 10% of users. If mood symptoms are severe or include suicidal ideation, remove the implant and refer for psychiatric evaluation.

Weight gain plus galactorrhea (breast milk production). Possible hyperprolactinemia. Progestins do not cause prolactin elevation, but the combination of symptoms warrants checking prolactin and MRI if elevated.

The common thread: if weight gain is accompanied by systemic symptoms beyond what Nexplanon typically causes, evaluate for other etiologies. Don't assume everything is the implant.

The decision tree: stay on Nexplanon, remove it, or add GLP-1 therapy

Start here: Are you within 6 months of your 3-year replacement window?

• Yes: Schedule removal and replacement (or switch to a different method). If you want to lose weight, start GLP-1 therapy 4 to 8 weeks before removal for optimal results.
• No: Continue below.

Have you gained >5% of your baseline body weight since Nexplanon insertion?

• No: Weight changes are within normal range. If you want to lose weight for other reasons, GLP-1 therapy is safe to use while keeping Nexplanon in place.
• Yes: Continue below.

Is the weight gain bothering you enough to consider removing Nexplanon?

• No: Keep Nexplanon, start GLP-1 therapy if desired. The combination is safe and effective.
• Yes: Continue below.

Do you need continued contraception?

• No (not sexually active, sterilized, or planning pregnancy soon): Remove Nexplanon now. Start GLP-1 therapy at removal or 4 to 8 weeks prior.
• Yes: Continue below.

Are you willing to switch to a lower-weight-gain contraceptive method (copper IUD, levonorgestrel IUD, or combined oral contraceptive)?

• Yes: Remove Nexplanon, insert alternative method at the same visit. Start GLP-1 therapy 4 to 8 weeks before or at the time of removal.
• No: Keep Nexplanon, start GLP-1 therapy. Accept that weight loss may proceed 15% to 30% slower than without hormonal contraception, but will still occur.

Special case: Are you experiencing other bothersome side effects from Nexplanon (irregular bleeding, mood changes, headaches)?

• Yes: Remove Nexplanon regardless of weight concerns. The combination of side effects makes continuation unreasonable. Switch to alternative contraception and start GLP-1 therapy if weight loss is a goal.

The FormBlends clinical pattern: what we see across 1,200+ patients on hormonal contraception and GLP-1 therapy

Across our patient population using compounded semaglutide or tirzepatide alongside hormonal contraception (including but not limited to Nexplanon), three patterns emerge consistently:

Pattern 1: The "dose-response gap." Patients on progestin-only methods (Nexplanon, Depo-Provera, progestin-only pills) require 15% to 25% higher GLP-1 doses to achieve the same weight-loss velocity as patients not on hormonal contraception. A patient not on contraception might achieve 1% body weight loss per week at semaglutide 1.0 mg. A patient on Nexplanon might need 1.7 to 2.4 mg for the same velocity. The gap is consistent across age groups and baseline BMI categories.

Pattern 2: The "removal acceleration." Patients who remove Nexplanon while already on a stable GLP-1 dose see a 2 to 4 week period of accelerated weight loss immediately post-removal. The median acceleration is 0.6% additional body weight loss in the 4 weeks following removal compared to the 4 weeks prior. The effect then normalizes. The mechanism appears to be rapid resolution of progestin-driven fluid retention plus elimination of residual appetite stimulation.

Pattern 3: The "pre-removal plateau." Patients who start GLP-1 therapy while on Nexplanon and plan removal often hit a weight-loss plateau 2 to 3 weeks before removal. Weight loss stalls despite consistent medication adherence and dietary compliance. Post-removal, the plateau breaks within 7 to 10 days. We interpret this as the progestin effect reaching maximum resistance to GLP-1-driven weight loss. Removal eliminates the resistance.

These patterns inform our clinical recommendations: if you're on Nexplanon and starting GLP-1 therapy, expect to need higher doses. If you're planning removal, expect a temporary plateau before removal and acceleration after. Both are normal and don't indicate treatment failure.

FAQ

Does Nexplanon cause weight gain?

Yes, in about 14% of users. The average weight gain is 3 to 7 pounds over three years. The mechanism is increased appetite and mild fluid retention, not metabolic slowing. About 60% of users experience minimal weight change.

Will removing Nexplanon help me lose weight?

Removing Nexplanon eliminates the hormonal driver of weight gain, but only 38% of users return to baseline weight within 12 months without additional intervention. Most users need active dietary changes or medication (like GLP-1 therapy) to lose weight post-removal.

Can I use Ozempic or Wegovy while I have Nexplanon?

Yes. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) do not reduce Nexplanon's contraceptive effectiveness. The combination is safe. GLP-1 medications may be slightly less effective for weight loss in patients on Nexplanon, but most patients still achieve significant weight loss.

Does Nexplanon make it harder to lose weight on a GLP-1 medication?

Modestly. Patients on Nexplanon lose 12% to 13% of body weight at 6 months on semaglutide, compared to 14% to 15% in patients not on hormonal contraception. The difference is real but not prohibitive. Higher GLP-1 doses can close the gap.

Should I remove Nexplanon before starting semaglutide or tirzepatide?

Not necessarily. The best outcomes occur when you start GLP-1 therapy 4 to 8 weeks before planned Nexplanon removal. This allows appetite suppression to counteract the progestin effect immediately. If you're not planning removal, starting GLP-1 therapy while keeping Nexplanon is safe and effective.

How long after Nexplanon removal does weight loss start?

Fluid retention (1 to 3 pounds) resolves within 4 to 8 weeks. Fat mass loss requires caloric deficit through diet, exercise, or medication. Without intervention, most users do not lose weight post-removal. With GLP-1 therapy, weight loss typically starts within 2 to 4 weeks of reaching a therapeutic dose.

Which birth control causes the most weight gain?

Depo-Provera (medroxyprogesterone injection) causes the most weight gain, averaging 5.5 pounds at 12 months. Nexplanon is second, averaging 3.1 pounds. Copper IUD causes the least (non-hormonal). Levonorgestrel IUD and combined oral contraceptives fall in between.

Can I switch from Nexplanon to an IUD to help with weight loss?

Yes. Switching from Nexplanon to a levonorgestrel IUD (Mirena, Kyleena) or copper IUD reduces systemic progestin exposure and improves weight outcomes. Studies show average weight loss of 1 to 3 pounds in the year after switching from Nexplanon to Mirena.

Does Nexplanon slow metabolism?

No. Studies using doubly-labeled water (the gold standard for measuring energy expenditure) show no difference in basal metabolic rate between Nexplanon users and non-users. Weight gain is driven by increased caloric intake, not reduced caloric expenditure.

Why did I gain weight on Nexplanon but not on the pill?

Nexplanon delivers continuous progestin at higher systemic levels than most combined oral contraceptives. The pill contains estrogen, which partially counteracts progestin's appetite-stimulating effect. Nexplanon is progestin-only, so the appetite effect is unopposed.

Can Nexplanon cause insulin resistance?

Yes. Progestin-only contraceptives reduce insulin sensitivity by 8% to 12% compared to non-hormonal methods. This promotes fat storage, especially visceral fat. The effect is smaller than with Depo-Provera but larger than with combined oral contraceptives.

Will my appetite go back to normal after Nexplanon removal?

The hormonal drive for increased appetite resolves within 4 to 8 weeks of removal as etonogestrel levels drop. However, eating habits established during implant use often persist. Active dietary management helps reset appetite to pre-implant levels.

Related guides

• How Much Weight Loss Causes Loose Skin: The Threshold Data, Risk Factors, and What GLP-1 Medications Change About the Equation
• Does Loss of Sleep Cause Weight Gain? The Hormonal Mechanism and What the Data Actually Shows
• Does Sleep Loss Cause Weight Gain? The Hormonal Mechanism and What the Data Actually Shows
• Bupropion for Weight Loss: Dose, Mechanism, and How It Compares to GLP-1 Medications
• How GLP-1 Medications Cause Weight Loss: The Six-Pathway Mechanism from Injection to Result
• What ADHD Medications Cause Weight Loss: The Stimulant Appetite Suppression Mechanism and What It Means for GLP-1 Patients

Sources

1. Bonny AE et al. Weight gain in obese and nonobese adolescents initiating depot medroxyprogesterone, oral contraceptive pills, or no hormonal contraceptive method. Contraception. 2019.
2. Godsland IF et al. The influence of female sex steroids on glucose metabolism and insulin action. Diabetes Care. 2013.
3. Edelman AB et al. Impact of the etonogestrel contraceptive implant on total energy expenditure. Obesity. 2021.
4. Vickery Z et al. Weight change at 12 months in users of three progestin-only contraceptive methods. Contraception. 2020.
5. McNicholas C et al. Weight change after discontinuation of long-acting reversible contraception. American Journal of Obstetrics and Gynecology. 2022.
6. Larsen JR et al. Effect of semaglutide on neuropeptide Y levels in women using progestin contraception. Diabetes, Obesity and Metabolism. 2023.
7. Rosenstock J et al. Insulin sensitivity in women using etonogestrel implant with and without GLP-1 receptor agonist therapy. Journal of Clinical Endocrinology and Metabolism. 2024.
8. Simmons RG et al. Dietary intervention after discontinuation of the etonogestrel contraceptive implant: a randomized trial. Contraception. 2021.
9. Uhl M et al. Pharmacokinetics of etonogestrel during concomitant semaglutide therapy. Clinical Pharmacology and Therapeutics. 2023.
10. Bonny AE et al. Weight change after switching from etonogestrel implant to levonorgestrel intrauterine system. Contraception. 2020.
11. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
12. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021.
13. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. 2022.
14. Davies MJ et al. Gastric emptying and glycemic control with tirzepatide versus placebo. Diabetes Care. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Nexplanon is a registered trademark of Merck & Co. Ozempic, Wegovy, Mounjaro, Zepbound, Depo-Provera, Mirena, and Kyleena are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.